Also trades as: TATVA.NS (NSE) · $vol 2M
TATVA.BO BSE
Tatva Chintan Pharma Chem Limited
1W: +0.9%
1M: +9.3%
3M: +40.1%
YTD: +46.0%
1Y: +63.7%
3Y: +4.9%
₹1,739.20 ($18.08)
-42.65 (-2.39%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$10.0B
+20.0% ▲
5Y CAGR: +26.1%
Total Liabilities
$2.2B
+127.8% ▲
5Y CAGR: +8.3%
Shareholders Equity
$7.8B
+5.8% ▲
5Y CAGR: +36.3%
Cash & Investments
$88M
-24.9% ▼
5Y CAGR: +10.6%
Total Debt
$1.2B
+230.8% ▲
5Y CAGR: +5.9%
Net Debt
$1.1B
+346.1% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $630M | $274M | $353M | $114M | $88M |
| Short-Term Investments | $8M | $138M | $104M | $3M | $0 |
| Cash & ST Investments | $638M | $412M | $457M | $117M | $88M |
| Net Receivables | $613M | $880M | $728M | $828M | $1.2B |
| Inventory | $1.7B | $1.6B | $1.5B | $1.3B | $2.0B |
| Other Current Assets | $1.1B | $60M | $204M | $368M | $254M |
| Total Current Assets | $4.4B | $3.1B | $3.0B | $2.7B | $3.5B |
| Property, Plant & Equip. | $2.1B | $4.3B | $5.0B | $5.5B | $6.3B |
| Goodwill & Intangibles | $3M | $5M | $40M | $59M | $68M |
| Long-Term Investments | -$1.1B | -$178M | $39M | $10K | $40M |
| Other Non-Current Assets | $1.1B | $212M | $11M | $180M | $63M |
| Total Non-Current Assets | $2.2B | $4.4B | $5.2B | $5.7B | $6.5B |
| Total Assets | $6.6B | $7.6B | $8.2B | $8.4B | $10.0B |
| — Liabilities — | |||||
| Accounts Payable | $445M | $322M | $450M | $327M | $582M |
| Short-Term Debt | $1.1B | $1.7B | $136M | $364M | $1.2B |
| Deferred Revenue | $21M | $41M | $38M | $0 | $0 |
| Other Current Liabilities | $164M | $367M | $122M | $265M | $392M |
| Total Current Liabilities | $1.7B | $2.4B | $797M | $960M | $2.1B |
| Long-Term Debt | $131M | $42M | $6M | $0 | $50M |
| Other Non-Current Liab. | $7M | $11M | $13M | $14M | $38M |
| Total Non-Current Liabilities | $138M | $54M | $20M | $14M | $88M |
| Total Liabilities | $1.9B | $2.4B | $816M | $974M | $2.2B |
| — Equity — | |||||
| Common Stock | $222M | $222M | $234M | $234M | $234M |
| Retained Earnings | $2.4B | $2.8B | $3.1B | $3.1B | $0 |
| Accumulated OCI | $4M | $11M | $11M | $25M | $7.6B |
| Total Stockholders Equity | $4.7B | $5.1B | $7.4B | $7.4B | $7.8B |
| Total Liabilities & Equity | $6.6B | $7.6B | $8.2B | $8.4B | $10.0B |
| — Key Metrics — | |||||
| Total Debt | $1.2B | $1.7B | $143M | $364M | $1.2B |
| Net Debt | $569M | $1.4B | -$210M | $223M | $1.1B |
| Total Investments | -$1.1B | -$39M | $143M | $3M | $40M |